advertisement
Advances in Therapy 28
Showing records 1 to 25 | Display all abstracts in Advances in Therapy66744 24-h Efficacy of Glaucoma Treatment Options
Konstas AG
Advances in Therapy 2016; 33: 481-517
67253 Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
Sheppard JD
Advances in Therapy 2016; 33: 532-552
67485 Boston Keratoprosthesis Outcomes in Severe Ocular Chemical Burns in Southern China: A Retrospective Study
Gu J
Advances in Therapy 2016; 33: 760-773
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Naito T
Advances in Therapy 2016; 33: 435-446
67464 Quality of Life in Glaucoma: A Review of the Literature
Quaranta L
Advances in Therapy 2016; 33: 959-981
67485 Boston Keratoprosthesis Outcomes in Severe Ocular Chemical Burns in Southern China: A Retrospective Study
Zhai J
Advances in Therapy 2016; 33: 760-773
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Okuma S
Advances in Therapy 2016; 33: 435-446
67253 Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
Comstock TL
Advances in Therapy 2016; 33: 532-552
66744 24-h Efficacy of Glaucoma Treatment Options
Quaranta L
Advances in Therapy 2016; 33: 481-517
67464 Quality of Life in Glaucoma: A Review of the Literature
Riva I; Gerardi C
Advances in Therapy 2016; 33: 959-981
67253 Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
Cavet ME
Advances in Therapy 2016; 33: 532-552
67485 Boston Keratoprosthesis Outcomes in Severe Ocular Chemical Burns in Southern China: A Retrospective Study
Zhou S
Advances in Therapy 2016; 33: 760-773
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Nagayama M
Advances in Therapy 2016; 33: 435-446
66744 24-h Efficacy of Glaucoma Treatment Options
Bozkurt B
Advances in Therapy 2016; 33: 481-517
67464 Quality of Life in Glaucoma: A Review of the Literature
Oddone F
Advances in Therapy 2016; 33: 959-981
66744 24-h Efficacy of Glaucoma Treatment Options
Katsanos A
Advances in Therapy 2016; 33: 481-517
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Mizoue S
Advances in Therapy 2016; 33: 435-446
67485 Boston Keratoprosthesis Outcomes in Severe Ocular Chemical Burns in Southern China: A Retrospective Study
Chen J
Advances in Therapy 2016; 33: 760-773
66744 24-h Efficacy of Glaucoma Treatment Options
Garcia-Feijoo J
Advances in Therapy 2016; 33: 481-517
67464 Quality of Life in Glaucoma: A Review of the Literature
Floriano I
Advances in Therapy 2016; 33: 959-981
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Ozaki M
Advances in Therapy 2016; 33: 435-446
66744 24-h Efficacy of Glaucoma Treatment Options
Rossetti L
Advances in Therapy 2016; 33: 481-517
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Namiguchi K
Advances in Therapy 2016; 33: 435-446
67464 Quality of Life in Glaucoma: A Review of the Literature
Konstas AG
Advances in Therapy 2016; 33: 959-981
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Miyamoto K
Advances in Therapy 2016; 33: 435-446
